Treating primary hypercholesterolaemia and mixed dyslipidaemia (NICE TA393)
Alirocumab is recommended as an option for treating primary hypercholesterolaemia or mixed dyslipidaemia, only if:
Low-density lipoprotein concentrations are persistently above the thresholds specified in table 1 (see NICE TA 393) despite maximal tolerated lipid-lowering therapy. That is, either the maximum dose has been reached or further titration is limited by intolerance (as defined in NICE’s guideline on familial hypercholesterolaemia: identification and management).
The company provides alirocumab with the discount agreed in the patient access scheme.
This guidance is not intended to affect the position of patients whose treatment with alirocumab was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.
To be used in accordance with the 'Summary of National Guidance for Lipid Management for Primary and Secondary Prevention of CVD'
Reason for decision: